Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives.

Publication date: Feb 11, 2020

Liquid biopsies are still far from widely implanted in the clinical arena. Issues related to the added sensitivity of this test beyond conventional methods have not been fully resolved. Additionally, issues related to the specificity of these results especially as many cancers may share common mutation need further investigations. One way to resolve this may include the development and testing of large gene panels to add higher specificity. On the other hand, further studies are needed to support the idea that ctDNA or circulating tumor cells may constitute a better representation of the tumor subpopulation that is capable of metastasizing, which will strongly support its clinical value. Finally, survival studies showing a positive impact of this technology will also justify its widespread implementation in clinical practice.

Alrabadi, N., Haddad, R., and Alomari, A.K. Detection of Gene Mutations in Liquid Biopsy of Melanoma Patients: Overview and Future Perspectives. 25784. 2020 Curr Treat Options Oncol (21):3.

Concepts Keywords
Arena Metastasis
Biopsies Melanoma
Biopsy Liquid biopsy
Melanoma Circulating tumor DNA
Metastasizing RTT
Mutation Medical signs
Subpopulation Anatomical pathology
Tumor Oncology
Medical specialties
Clinical medicine
Medicine
Representation tumor
Specificity cancers

Semantics

Type Source Name
disease MESH Biopsy
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH cancers
disease MESH development
disease MESH circulating tumor cells
drug DRUGBANK Tropicamide

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *